Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly insulin icodec with DoseGuide versus once-daily basal insulin analogues in insulin-naive type 2 diabetes
2020-000476-38Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of insulin icodec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Dec 2020; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-000476-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000476-38.